Copyright
©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 964-972
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Table 1 Summary of demographic and clinical characteristics at baseline of chronic hepatitis B patients on tenofovir alafenamide or entecavir therapy
Characteristic | TAF, n = 214 | ETV, n = 122 | P value |
Age in yr | 43.38 ± 10.42 | 49.96 ± 11.82 | 0.001 |
Male | 158 (73.83) | 96 (78.69) | 0.387 |
BMI in kg/m2 | 22.97 ± 2.93 | 23.78 ± 3.30 | 0.152 |
Smoking | 16 (7.48) | 15 (12.30) | 0.203 |
Drinking | 13 (6.07) | 14 (11.48) | 0.123 |
ALT in U/L | 36.60 ± 36.87 | 30.44 ± 20.00 | 0.089 |
AST in U/L | 28.01 ± 26.41 | 24.50 ± 13.58 | 0.172 |
logHBsAg in ng/mL | 3.07 ± 0.92 | 3.04 ± 0.84 | 0.787 |
logDNA in IU/mL | 1.94 ± 1.23 | 1.86 ± 1.05 | 0.56 |
CREA in μmol/L | 73.68 ± 15.87 | 74.82 ± 16.78 | 0.535 |
UA in μmol/L | 353.52 ± 89.10 | 357.23 ± 84.29 | 0.708 |
GFR in mL/min | 103.48 ± 15.01 | 97.86 ± 14.17 | 0.001 |
CK in U/L | 157.23 ± 444.75 | 122.91 ± 71.31 | 0.401 |
FBG in mmol/L | 5.18 ± 0.80 | 5.52 ± 1.61 | 0.011 |
Concurrent diseases | |||
Hypertension | 17 (7.94) | 21 (17.21) | 0.016 |
DM | 20 (9.35) | 13 (10.66) | 0.844 |
NAFLD | 75 (35.05) | 32 (26.23) | 0.122 |
Cirrhosis | 54 (25.23) | 50 (40.98) | 0.004 |
Table 2 Comparison of serum lipid profile before and after 1 year of anti-viral therapy either tenofovir alafenamide or entecavir
Characteristic | TAF, n = 214, statistic | P value1 | ETV, n = 122, statistic | P value1 | P value2 |
Pre-Tx TCHO in mmol/L | 4.51 ± 0.93 | 0.001 | 4.41 ± 1.03 | 0.275 | 0.376 |
Post-Tx TCHO in mmol/L | 4.67 ± 0.90 | 4.36 ± 1.05 | 0.006 | ||
Pre-Tx TG in mmol/L | 1.25 ± 0.67 | 0.014 | 1.33 ± 0.75 | 0.052 | 0.35 |
Post-Tx TG in mmol/L | 1.37 ± 0.81 | 1.24 ± 0.61 | 0.126 | ||
Pre-Tx HDL in mmol/L | 1.32 ± 0.40 | 0.794 | 1.26 ± 0.40 | 0.879 | 0.246 |
Post-Tx HDL in mmol/L | 1.32 ± 0.36 | 1.27 ± 0.41 | 0.285 | ||
Pre-Tx LDL in mmol/L | 3.12 ± 0.90 | 0.785 | 3.06 ± 1.01 | 0.078 | 0.543 |
Post-Tx LDL in mmol/L | 3.14 ± 0.92 | 3.15 ± 1.00 | 0.906 | ||
Pre-Tx NAFLD | 75 (35.05) | 0.125 | 32 (26.23) | 1 | 0.122 |
Post-Tx NAFLD | 70 (32.71) | 31 (25.41) | 0.16 |
Table 3 Impact of tenofovir alafenamide on achieving a higher level of total cholesterol in chronic hepatitis B patients
- Citation: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972
- URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i8.964